Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GO-201
- Development stage
- Preclinical
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Peptides
01
Overview
GO-201 is a synthetic peptide inhibitor that directly targets the Mucin 1 (MUC1) oncoprotein, which is aberrantly overexpressed in approximately 90% of human breast cancers. GO-201 binds to the MUC1 cytoplasmic domain, blocking the formation of MUC1 oligomers, attenuating nuclear localization, disrupting redox balance, and activating DNA damage response in cancer cells. This leads to growth arrest and necrotic cell death in MUC1-expressing tumor cells, with no effect on nonmalignant mammary or MUC1-null cells. In preclinical models, GO-201 showed efficacy in inducing tumor regression.
- Other names
- GO-201GO201GO 201
02
Targets
MUC1-CD (Mucin-1 cytoplasmic domain)
Beyond the preview
Go deeper on GO-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GO-201.